216 related articles for article (PubMed ID: 29392871)
1. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
Ji Y; Jin JY; Hyman DM; Kim G; Suri A
Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
[No Abstract] [Full Text] [Related]
2. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
3. What was wrong and might now go right with clinical trials for lupus?
Merrill JT
Curr Rheumatol Rep; 2009 Aug; 11(4):235-7. PubMed ID: 19691925
[No Abstract] [Full Text] [Related]
4. Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
Ochoa de Olza M; Oliva M; Hierro C; Matos I; Martin-Liberal J; Garralda E
Ann Oncol; 2018 Aug; 29(8):1727-1740. PubMed ID: 29945232
[TBL] [Abstract][Full Text] [Related]
5. Development of rational drug combinations with investigational targeted agents.
Clark A; Ellis M; Erlichman C; Lutzker S; Zwiebel J
Oncologist; 2010; 15(5):496-9. PubMed ID: 20489187
[TBL] [Abstract][Full Text] [Related]
6. Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.
Thall PF; Garrett-Mayer E; Wages NA; Halabi S; Cheung YK
Clin Trials; 2024 Jun; 21(3):267-272. PubMed ID: 38570906
[TBL] [Abstract][Full Text] [Related]
7. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
[No Abstract] [Full Text] [Related]
8. A Tale of Two Trials.
Wofsy D
Arthritis Rheumatol; 2020 Aug; 72(8):1256-1257. PubMed ID: 32182394
[No Abstract] [Full Text] [Related]
9. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
[TBL] [Abstract][Full Text] [Related]
10. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
11. First-in-man and first-of-class-in-man clinical trials in oncology.
Mross K
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):68-70. PubMed ID: 19203543
[No Abstract] [Full Text] [Related]
12. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
Ellis LM; Bernstein DS; Voest EE; Berlin JD; Sargent D; Cortazar P; Garrett-Mayer E; Herbst RS; Lilenbaum RC; Sima C; Venook AP; Gonen M; Schilsky RL; Meropol NJ; Schnipper LE
J Clin Oncol; 2014 Apr; 32(12):1277-80. PubMed ID: 24638016
[No Abstract] [Full Text] [Related]
13. A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology.
Ottaiano A; Budillon A; Normanno N; Iaffaioli VR; Caraglia M
Ann Oncol; 2007 May; 18(5):960-1. PubMed ID: 17437968
[No Abstract] [Full Text] [Related]
14. Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.
Zhang SX; Fergusson D; Kimmelman J
J Natl Cancer Inst; 2020 Sep; 112(9):886-892. PubMed ID: 32239146
[TBL] [Abstract][Full Text] [Related]
15. American society of clinical oncology--41st annual meeting. Immunology.
Shah S; Yager N
IDrugs; 2005 Jul; 8(7):528-30. PubMed ID: 15973554
[No Abstract] [Full Text] [Related]
16. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
Huntington SF; Davidoff AJ; Gross CP
J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
[No Abstract] [Full Text] [Related]
17. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.
Thompson JA
J Natl Compr Canc Netw; 2018 May; 16(5S):594-596. PubMed ID: 29784734
[TBL] [Abstract][Full Text] [Related]
18. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
20. Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).
Liu X; Belani CP
Curr Mol Pharmacol; 2016; 9(3):182. PubMed ID: 26177639
[No Abstract] [Full Text] [Related]
[Next] [New Search]
